China SXT Pharmaceuticals, Inc. (SXTC)
- Previous Close
1.4100 - Open
1.9700 - Bid 1.5700 x 200
- Ask 2.5900 x 200
- Day's Range
1.7100 - 2.2300 - 52 Week Range
0.3000 - 5.6980 - Volume
23,025,513 - Avg. Volume
4,568,190 - Market Cap (intraday)
28.215M - Beta (5Y Monthly) 1.25
- PE Ratio (TTM)
0.02 - EPS (TTM)
124.5000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, ShaRen, and ChenXiang. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.
www.sxtchina.com75
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: SXTC
View More
Performance Overview: SXTC
Trailing total returns as of 5/6/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SXTC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SXTC
View MoreValuation Measures
Market Cap
28.21M
Enterprise Value
18.79M
Trailing P/E
0.02
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.55
Price/Book (mrq)
2.77
Enterprise Value/Revenue
10.33
Enterprise Value/EBITDA
2.96
Financial Highlights
Profitability and Income Statement
Profit Margin
318.69%
Return on Assets (ttm)
18.15%
Return on Equity (ttm)
57.63%
Revenue (ttm)
1.82M
Net Income Avi to Common (ttm)
5.8M
Diluted EPS (ttm)
124.5000
Balance Sheet and Cash Flow
Total Cash (mrq)
18.51M
Total Debt/Equity (mrq)
65.66%
Levered Free Cash Flow (ttm)
3.27M